Registration is now open for industry and academic researchers to attend our 2016 SMA Researcher Meeting, which will be held June 16-18 in Anaheim, CA, at the Disneyland Hotel. The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. The 2015 SMA Researcher Meeting set a record, with over […]
Registration Open for the 2016 SMA Researcher Meeting Read More »
The House of Representatives has passed the Ensuring Access to Clinical Trials Act of 2015 (EACT). This bill already passed the Senate in July, and will now go to President Obama to be signed into law. This bill allows individuals to receive up to $2,000 as compensation for participating in a clinical trial, without those
House of Representatives Passes Ensuring Access to Clinical Trials Act Read More »
A note from Rich Rubenstein, Kenneth Hobby, and the entire Cure SMA team: Cure SMA has had the honor to have Jessica Moyer and her family as one of our volunteer chapter leaders for almost 14 years. Jessica has been critical to the success of our organization, thanks to her efforts locally and nationally. Cure
Thank You to Jessica Moyer and Family Read More »
Thanks to our vibrant community, August was one of our largest and best awareness months ever, with unprecedented levels of public awareness and outreach for SMA. Toward the end of August, we challenged our community to seize this momentum, and convert awareness into action and advocacy. One of these opportunities to convert awareness into action
FDA Engagement Update: The Voices of SMA Read More »
We will be posting a series of summaries from our 2015 researcher meeting, highlighting some of the most interesting new developments and discoveries presented there. This update covers the second half of a session on SMN Partners and Therapeutic Targets. The session was moderated by Rashmi Kothary, PhD. SMN Partners and Candidate Therapeutic Targets, Part
2015 SMA Researcher Meeting Summary: SMN Partners and Targets, Part 2 Read More »
Originally published on January 18, 2013. Cure SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program, including drug discovery programs to make practical new therapies. Dr. Rubin’s project at Harvard University is the first of three drug discovery awards that will be given
Originally published on January 3, 2013. Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Cure SMA. Cure SMA funded and directed the preclinical development of RG3039 with an investment of more than $13 million. This
Pfizer Licenses Cure SMA Quinazoline Drug Program from Repligen Read More »
Originally published on April 4, 2013. Award to support testing of Tirasemtiv in mouse models of Spinal Muscular Atrophy. Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA announced the award of a grant from Cure SMA to Cytokinetics to support preclinical research on muscle function in a mouse model of spinal muscular atrophy (SMA) to be
Originally published on April 23, 2013. Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced in April the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). The study, which will begin enrolling patients soon, is a Phase 2 study in eight patients with infantile-onset SMA. The study, which initiates the Phase
ISIS Pharmaceuticals Initiates Clinical Study in Infants with Spinal Muscular Atrophy Read More »
Originally published on May 2, 2013. Cure SMA is dedicated to creating a treatment and cure for spinal muscular atrophy by funding and advancing a comprehensive research program, including drug discovery programs to make practical new therapies. This is the third of four drug discovery project awarded by Cure SMA in 2013 with a total
